FILE PHOTO: Psilocybin or "magic mushrooms" are seen in an undated photo provided by the U.S. Drug Enforcement Agency (DEA) in Washington, U.S. May 7, 2019. DEA | Reuters The U.S. Food and Drug Administration on Friday announced a series of measures aimed at accelerating the development of psychedelic treatments for serious mental illness. That comes after President Donald Trump signed an executiv...
FILE PHOTO: Psilocybin or "magic mushrooms" are seen in an undated photo provided by the U.S. Drug Enforcement Agency (DEA) in Washington, U.S. May 7, 2019. DEA | Reuters The U.S. Food and Drug Administration on Friday announced a series of measures aimed at accelerating the development of psychedelic treatments for serious mental illness. That comes after President Donald Trump signed an executive order on Saturday directing federal health agencies to expand access to emerging therapies. The move marks a significant shift toward supporting psychedelic-based medicines for conditions such as treatment-resistant depression, post-traumatic stress disorder and other substance use disorders, the FDA said. "Under President Trump's leadership, we are accelerating the research, approval and responsible access to promising mental health treatments," Robert F. Kennedy Jr., secretary of the U.S. Department of Health and Human Services, said in the release. "The FDA will prioritize therapies with Breakthrough Therapy designation, where early evidence shows meaningful improvement." As part of the announcement, the FDA said it would issue national priority vouchers to companies studying psilocybin for depression and methylone for PTSD. The agency also cleared an early-stage clinical trial for noribogaine hydrochloride, a derivative of ibogaine, as a potential treatment for alcohol use disorder. This is the first time a compound like it has been authorized for study in the U.S. "These medications have the potential to address the nation's mental health crisis," FDA Commissioner Marty Makary said in the announcement. "It is critical that their development is grounded in sound science and rigorous clinical evidence." The FDA said allowing these studies to proceed does not mean the drugs are approved or proven safe and effective. Officials said data with be closely monitored as research advances. Choose CNBC as your preferred source on Google and never miss a moment from the most tru...
Intel Corp. is set to hold fixed-income investor calls Friday after delivering a sales forecast that shattered Wall Street expectations. The chipmaker asked Citigroup Inc. , JPMorgan Chase & Co. , Barclays Plc , Bank of America Corp. and Deutsche Bank AG to arrange the calls, according to a person with knowledge of the matter, who asked not to be identified because they’re not authorized to speak ...
Intel Corp. is set to hold fixed-income investor calls Friday after delivering a sales forecast that shattered Wall Street expectations. The chipmaker asked Citigroup Inc. , JPMorgan Chase & Co. , Barclays Plc , Bank of America Corp. and Deutsche Bank AG to arrange the calls, according to a person with knowledge of the matter, who asked not to be identified because they’re not authorized to speak publicly. It wasn’t immediately clear what would be discussed, though such calls are typically a prelude to a bond sale. A representative for Intel did not immediately respond to a request for comment. Intel agreed earlier this month to pay $14.2 billion to buy back half of a plant in Ireland that it had previously sold to Apollo Global Management Inc. . Moody’s Ratings said at the time that it expected the firm to take on about $6.5 billion of new debt to help fund the purchase. The company’s shares soared in premarket trading Friday, putting its stock on pace to hit record highs. Intel’s revenue forecast suggests that Chief Executive Officer Lip-Bu Tan is making progress on a comeback plan that aims to position the firm to benefit from the buildout of artificial intelligence computing. Intel last sold dollar notes in February 2024 , according to Bloomberg-compiled data. Its foundry joint venture with Brookfield Infrastructure Partners raised nearly $12 billion through three offerings in 2024 and 2025 .